After signing a drug pricing deal with the White House, J&J will now offer some of its branded medicines at discounted rates ...
As we enter 2026, U.S. equities are expected to enter a phase marked by several complexities following the outsized gains in ...
Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...
Zacks.com on MSN
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic ...
The American drugmaker was one of 17 companies US President Donald Trump called on last summer to lower prices, and among the ...
JNJ agreed to drug discounts and tariff exemptions under a White House deal. ・The agreement builds on its existing $55 ...
In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...
Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...
Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...
The University of Pennsylvania is teaming up with BioNTech and Osage University Partners to launch a new venture fund. The ...
U.S. oil producers already reeling from low oil prices are facing renewed pressures, as President Donald Trump pushes them to ...
Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback